Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy

T cells expressing a CD19-specific chimeric antigen receptor (CAR19) are demonstrating remarkable efficacy in hematologic malignancies. Treatment is often associated with life-threatening cytokine release syndrome (CRS) which can be effectively treated with cytokine blockade using the antibodies, Si...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Immunol Methods
Autores principales: Chen, Fang, Teachey, David T., Pequignot, Edward, Frey, Noelle, Porter, David, Maude, Shannon L., Grupp, Stephan A., June, Carl H., Melenhorst, Jan J., Lacey, Simon F.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5490247/
https://ncbi.nlm.nih.gov/pubmed/27049586
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jim.2016.03.005
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares